A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

CBD Shows Promise for Schizophrenia, Alzheimer’s, and Brain Injury Patients

A meta-analysis of previous studies investigating cannabidiol’s (CBD) potential to improve cognitive function among schizophrenia and brain injury patients offers hope to doctors and patients. In experiments on both human patients and rat models of schizophrenia, Alzheimer’s Disease, hypoxic-ischemic brain injury, hepatic encephalopathy, sepsis, pneumococcal meningitis, and cerebral malaria, the administration of CBD reduced neuroinflammation and resulting deficits in spatial learning and memory, recognition memory, and associative learning. Read more or download PDF on the CED Foundation Archive:

In this same review, further investigating the effect of the non-psychoactive cannabidiol (CBD) on cognitive function suggests CBD counteracts the cognitive deficiencies induced by the psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC). Studies performed on humans and rat models demonstrated that CBD can improve episodic and recognition memory, verbal and visual learning and memory, and working memory, all skills which are usually impaired by THC content. For patients looking to reduce the aforementioned undesirable effects of cannabis, strains or products with high CBD and low THC content may be a viable solution.

Benjamin Caplan, MDA systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
read more

CBD Shows Potential for Schizophrenia Treatment

Research on schizophrenia-affected rat models shows potential for #CBD to minimize many #schizophrenia symptoms

Cannabidiol (CBD) may have potential as a schizophrenia therapeutic agent. Individuals with schizophrenia exhibit decreased activity in choline acetyltransferase (ChAT) activity, an enzyme associated with cognitive functioning. In rat models mimicking schizophrenia, affected rats treated with CBD exhibited normal ChAt activity, while their untreated counterparts exhibited reduced activity.   

CED Foundation Google Drive:

Read Here or Download:

Benjamin Caplan, MDCBD Shows Potential for Schizophrenia Treatment
read more